10-Q: Acadia Healthcare Q3 Net Income Plunges Amid Soaring Legal Costs

Acadia Healthcare Company, Inc. reported a significant decline in net income for the third quarter and first nine months of 2025, primarily driven by a sharp increase in legal and government investigation costs, despite revenue growth.

Summary

• Net income attributable to Acadia Healthcare Company, Inc. decreased by 46.8% to $36.2 million for the three months ended September 30, 2025, compared to $68.1 million in the prior year period.
• For the nine months ended September 30, 2025, net income attributable to Acadia Healthcare Company, Inc. fell by 66.5% to $74.7 million, down from $223.0 million in the same period of 2024.
• Revenue increased by 4.4% to $851.6 million for the three months, and by 4.7% to $2,491.3 million for the nine months ended September 30, 2025.
• Transaction, legal, and other costs surged to $42.9 million for the three months and $138.4 million for the nine months ended September 30, 2025, largely due to government investigations.
• The company added 908 beds and opened 14 Comprehensive Treatment Centers (CTCs) during the first nine months of 2025 as part of its growth strategy.
• A new $1.0 billion revolving credit facility and a $650.0 million term loan facility were established on February 28, 2025, refinancing prior debt.
• A share repurchase program authorized up to $300.0 million, with $50.4 million used to repurchase 1,706,625 shares during the nine months ended September 30, 2025.
• Retention bonuses were offered to key employees Tim Sides ($500,000), Brian Farley ($400,000), and Nasser Khan ($300,000), contingent on continued employment.

Sentiment

Score: 3

Explanation: Despite revenue growth and strategic expansion, the substantial decline in net income and earnings per share, primarily due to a dramatic increase in legal and government investigation costs, indicates significant operational headwinds and financial pressure. The ongoing legal and regulatory scrutiny presents considerable uncertainty.

Positives

• Revenue grew by 4.4% for the three months and 4.7% for the nine months ended September 30, 2025, demonstrating continued demand for services.
• Same facility revenue increased by 3.7% for the three months and 5.1% for the nine months, driven by growth in patient days and revenue per patient day.
• Expanded operations by adding 908 beds and opening 14 new Comprehensive Treatment Centers (CTCs) during the first nine months of 2025.
• Net cash provided by operating activities significantly increased to $218.2 million for the nine months ended September 30, 2025, compared to $13.0 million in the prior year.
• Successfully refinanced its prior credit facility with a new $1.65 billion credit facility, extending maturities to February 28, 2030.
• Maintained compliance with all financial covenants, with a Consolidated Total Net Leverage Ratio of 3.4x at September 30, 2025, well below the 5.0x limit.
• Initiated a $300.0 million share repurchase program, demonstrating commitment to shareholder returns.

Negatives

• Net income attributable to Acadia Healthcare Company, Inc. decreased substantially by 46.8% to $36.2 million for the three months ended September 30, 2025, and by 66.5% to $74.7 million for the nine months ended September 30, 2025.
• Basic and diluted earnings per share both declined by 45.9% for the three months and approximately 66% for the nine months ended September 30, 2025.
• Transaction, legal, and other costs surged by $34.7 million (3 months) and $121.2 million (9 months) year-over-year, primarily due to government investigations.
• Salaries, wages, and benefits (excluding equity-based compensation) increased as a percentage of revenue to 53.6% for the three and nine months ended September 30, 2025, from 51.3% and 52.0% respectively, indicating higher labor costs.
• Interest expense, net, increased by $6.7 million for the three months and $14.6 million for the nine months ended September 30, 2025, due to higher interest rates on new debt.
• Incurred $1.3 million in debt extinguishment costs related to the refinancing of the prior credit facility.
• Recorded $3.5 million in legal settlements expense for the nine months ended September 30, 2025, related to the Desert Hills Litigation.

Risks

• Impact of internal or governmental investigations, regulatory actions, whistleblower lawsuits, and other legal proceedings.
• Competition for staffing, labor shortages, and higher turnover rates affecting labor costs and profitability.
• Impact of inflationary pressure and interest rate volatility.
• Indebtedness, ability to meet debt obligations, and ability to incur substantially more debt.
• Impact of payments received from government and third-party payors on revenue and results of operations.
• Volatility in global capital and credit markets, and significant macroeconomic and political conditions.
• Difficulties in successfully integrating acquired facilities or realizing potential benefits and synergies of acquisitions and joint ventures.
• Ability to recruit and retain quality psychiatrists, physicians, nurses, counselors, and other medical support personnel.
• Occurrence of patient incidents, which could result in negative media coverage, adversely affect securities price, and lead to regulatory burdens and governmental investigations.
• Impact of class action and other claims, including for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort, and employee-related claims.
• Outcome of pending litigation, including the St. Clair County Employees Retirement System securities litigation and the Kachrodia securities litigation.
• Impact of carrying a large self-insured retention, potential for significant uninsured amounts, premium increases, and unavailability of insurance on acceptable terms.
• Impact of enactment, amendment, or expiration of statutes and regulations affecting the healthcare industry, and potential reductions to Medicare and Medicaid payment rates and coverage.
• Impact of the restructuring, consolidation, and elimination of federal agencies that regulate the healthcare industry.
• Operational, financial, legal, and regulatory risks associated with acquisition, joint venture, and wholly-owned de novo strategies.
• Impact of state efforts to regulate the construction or expansion of healthcare facilities.
• Potential impact of activist stockholder actions or tactics.
• Impact of disruptions on inpatient and outpatient volumes caused by pandemics, epidemics, or outbreaks of infectious diseases.
• Dependence on key management personnel, key executives, and local facility management personnel.
• Restrictive covenants that may limit business and financing activities.
• Impact of adverse weather conditions and climate change, including natural disasters.
• Risk of a cybersecurity incident and any resulting adverse impact on operations or violation of information privacy laws.
• Impact on business if information systems fail or databases are destroyed or damaged.
• Ability to access capital on acceptable terms.
• Impact of a highly competitive industry on patient volumes.
• Ability to cultivate and maintain relationships with referral sources.
• Impact of the trend for insurance companies and managed care organizations to enter into sole source contracts.
• Impact of value-based purchasing programs on revenue.
• Potential inability to extend leases at expiration.
• Impact of controls designed to reduce inpatient services on revenue.
• Impact of different interpretations of accounting principles on results of operations or financial condition.
• Impact of environmental, health, and safety laws and regulations.
• Impact of laws and regulations relating to privacy and security of patient health information and standards for electronic transactions.
• Impact of a change in the mix of earnings, adverse changes in effective tax rate, and adverse developments in tax laws.
• Changes in interpretations, assumptions, and expectations regarding tax legislation and policy.
• Failure to maintain effective internal control over financial reporting.
• Impact of fluctuations in operating results, quarter-to-quarter earnings, and other factors on the price of securities.
• Impact of various executive orders affecting the broader healthcare industry.

Future Outlook

The company aims to become the indispensable behavioral healthcare provider for high-acuity and complex needs patients, pursuing growth through expansions of existing facilities, joint venture partnerships, de novo facilities, acquisitions, and expanding its continuum of care. Management expects to leverage increased size and geographic scale for national marketing, out-of-state referrals, and broader service offerings. The company anticipates minimal material impact from the One Big Beautiful Bill Act's Medicaid changes in 2026 due to exemptions for its patient populations, but is evaluating the impact of significant changes to Medicaid financing mechanisms beginning in 2028.

Management Comments

• We believe that we are well positioned to help meet the growing demand for behavioral healthcare services.
• We continue to navigate a tight labor market. While we experienced higher wage inflation compared to historical averages in recent years, we continue to see stability in our labor costs, and our proactive focus helps us manage through this environment.
• We remain focused on ensuring that we have the level of staff to meet the demand in our markets across 40 states and Puerto Rico.

Industry Context

The behavioral healthcare industry continues to experience growing demand, which Acadia Healthcare is actively addressing through facility expansions and new center openings. The company operates in a highly fragmented market, positioning itself as a leading pure-play provider. Legislative changes like the One Big Beautiful Bill Act introduce new regulatory complexities and potential shifts in Medicaid financing, which could impact the broader healthcare sector, though Acadia anticipates limited direct impact on its specific patient populations in the near term.

Legal Proceedings

• A sixth lawsuit, CNRAG, Inc. as Legal Guardian of A.C. v. Garcia et al., No. D-117-CV-2024-00045, was filed on January 30, 2024, alleging similar claims as the Desert Hills Litigation, with the company unable to reasonably estimate liability.
• In the St. Clair County Employees Retirement System v. Acadia Healthcare Company, Inc., et al. securities litigation, the court denied defendants' motion for summary judgment on October 16, 2025, with a trial set for November 18, 2025, if a stay is not granted. Plaintiffs are seeking damages ranging from $5.48 to $16.84 per share.
• A consolidated class action complaint, Kachrodia v. Acadia Healthcare Company, Inc., et al., was filed on July 10, 2025, alleging violations of the Exchange Act, with defendants filing a motion to dismiss on September 8, 2025.
• Multiple derivative actions (Davydov v. Jacobs, et al., Beard v. Jacobs, et al., Pfenning v. Jacobs, et al., Solak v. Jacobs, et al., Kachrodia v. Osteen, et al.) are pending, and stays will be lifted following the denial of summary judgment in the securities litigation.
• The DOJ Criminal Division and SEC issued subpoenas in September and December 2024, respectively, related to the company's acute care service line (admissions, length of stay, billing practices) and CTC service line, with the company conducting an internal investigation and unable to reasonably estimate liability.

Stakeholder Impact

• Shareholders: Significant decrease in net income and EPS, coupled with substantial legal costs, could negatively impact share price and investor confidence. The share repurchase program offers some mitigation.
• Employees: Retention bonuses for key personnel aim to stabilize leadership. Ongoing labor market tightness and wage inflation could affect employee costs and potentially morale if not managed effectively.
• Customers (Patients): Continued expansion of facilities and beds indicates an effort to meet growing demand for behavioral healthcare services.
• Creditors: Refinancing of debt and compliance with financial covenants (3.4x leverage ratio vs. 5.0x limit) indicates sound debt management, but increased overall debt levels and interest expense warrant monitoring.
• Regulatory Authorities: Ongoing government investigations and legal proceedings highlight increased scrutiny and potential for future penalties or operational restrictions.

Next Steps

• Trial for St. Clair County Employees Retirement System v. Acadia Healthcare Company, Inc., et al. set for November 18, 2025, if a stay is not granted.
• Plaintiffs' responsive brief due by November 7, 2025, for Kachrodia v. Acadia Healthcare Company, Inc., et al.
• Defendants' reply due by December 22, 2025, for Kachrodia v. Acadia Healthcare Company, Inc., et al.
• Stays will be lifted in derivative cases (Davydov v. Jacobs, et al., Beard v. Jacobs, et al., Pfenning v. Jacobs, et al., Solak v. Jacobs, et al., Kachrodia v. Osteen, et al.) following the denial of summary judgment in the securities litigation.
• Company is currently conducting a comprehensive internal investigation using external advisors regarding DOJ Criminal Division and SEC investigations.
• Company will continue to cooperate with authorities regarding government investigations and congressional inquiries.
• Work or community engagement requirements for Medicaid expansion population under OBBBA will begin to be phased in during 2026.
• Significant changes to Medicaid financing mechanisms under OBBBA, including restrictions on provider tax arrangements and caps on state directed payment programs, will begin in 2028.
• Tim Sides must remain continuously employed through March 31, 2026, to earn his retention bonus.
• Brian Farley and Nasser Khan must remain continuously employed through March 31, 2028, to earn their supplemental cash awards.

Key Dates

Recommendation

The substantial decline in net income and EPS, primarily due to a dramatic increase in legal and government investigation costs, signals significant underlying issues and financial uncertainty. While revenue growth and strategic expansion are positive, the magnitude of these unexpected expenses and the ongoing nature of the investigations present considerable downside risk. The company faces multiple class action lawsuits and derivative actions, with one trial set for November 2025, and cannot estimate the ultimate liability for several of these matters. This level of legal and regulatory overhang, combined with rising labor costs and increased interest expense, suggests a challenging outlook that could further erode shareholder value. Investors should consider reducing exposure until there is greater clarity on the financial impact and resolution of these legal and regulatory challenges.

Keywords

Behavioral Healthcare, Mental Health, Substance Abuse Treatment, SEC Filing, 10-Q, Acadia Healthcare, ACHC, Financial Results, Earnings, Revenue, Legal Costs, Government Investigations, Share Repurchase, Debt Refinancing, Healthcare Facilities, Inpatient Psychiatric, Outpatient Services, Retention Bonus